Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial symbols : Nvax save search
Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
Published: 2022-12-30 (Crawled : 13:20) - prnewswire.com
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: -1.34%
H: 7.4%
C: 7.19%
covid-19 vaccine trial influenza phase 2
Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster
Published: 2022-11-08 (Crawled : 14:20) - biospace.com/
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: -3.96%
H: 8.79%
C: 5.31%
covid-19 vaccine prototype trial
Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years
Published: 2022-08-04 (Crawled : 13:20) - biospace.com/
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: 0.31%
H: 3.16%
C: 1.03%
covid-19 global children vaccine six trial phase 2b
Novavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial
Published: 2022-04-22 (Crawled : 12:00) - biospace.com/
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: -12.19%
H: 4.08%
C: -1.27%
covid-19 vaccine trial phase 3
Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine
Published: 2022-04-20 (Crawled : 17:00) - prnewswire.com
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: -1.1%
H: 5.48%
C: -0.56%
covid-19 vaccine trial results
Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: -0.81%
H: 3.12%
C: 2.96%
covid-19 trial covid disease vaccine infection phase 3 infections
Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial
Published: 2022-02-10 (Crawled : 00:00) - biospace.com/
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: -4.98%
H: 0.0%
C: 0.0%
covid-19 trial covid event-19 positive results positive vaccine phase 3
Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study
Published: 2021-12-21 (Crawled : 23:00) - prnewswire.com
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: 0.11%
H: 1.0%
C: -4.17%
event-19 covid-19 trial covid vaccine phase 3
Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases
Published: 2021-09-24 (Crawled : 01:00) - prnewswire.com
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
disease infectious disease results vaccine influenza phase 3 trial lancet
Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza
Published: 2021-09-08 (Crawled : 13:00) - biospace.com/
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: 0.92%
H: 1.74%
C: -2.29%
covid phase 1 vaccine influenza trial phase 2 phase 3 covid-19
Novavax Statement on CDC Guidance Update for COVID-19 Clinical Trial Participants
Published: 2021-08-30 (Crawled : 21:00) - biospace.com/
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: -1.04%
H: 6.19%
C: 3.98%
covid trial covid-19
Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine
Published: 2021-06-30 (Crawled : 22:00) - prnewswire.com
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: 1.27%
H: 0.47%
C: 0.35%
covid results vaccine phase 3 trial
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
Published: 2021-06-14 (Crawled : 10:00) - prnewswire.com
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: 7.52%
H: 1.8%
C: -7.86%
covid disease vaccine phase 3 trial
New England Journal of Medicine Publishes Phase 2b Clinical Trial Results Demonstrating Efficacy of Novavax COVID-19 Vaccine Against the B.1.351 Variant
Published: 2021-05-05 (Crawled : 01:00) - biospace.com/
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: 3.47%
H: 4.31%
C: -8.13%
covid phase 2 results vaccine phase 2b trial trial results
Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine
Published: 2021-05-03 (Crawled : 12:57) - prnewswire.com
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: 0.66%
H: 0.54%
C: -18.19%
covid expansion vaccine phase 3 trial covid-19
Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet
Published: 2021-04-23 (Crawled : 10:00) - prnewswire.com
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: 0.1%
H: 3.12%
C: 0.05%
phase 2 results vaccine phase 2b trial trial results lancet malaria
Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
Published: 2021-02-26 (Crawled : 14:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.72%
H: 0.5%
C: -0.95%
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: 1.81%
H: 3.52%
C: 2.54%
covid phase 1 vaccine license trial phase 3 phase 2
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
Published: 2021-02-22 (Crawled : 12:03) - globenewswire.com
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: -3.56%
H: 3.41%
C: -8.55%
covid vaccine phase 3 trial enroll
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
Published: 2021-01-28 (Crawled : 22:01) - globenewswire.com
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: 42.56%
H: 23.27%
C: 15.65%
covid vaccine phase 3 trial covid-19
Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico
Published: 2020-12-28 (Crawled : 15:00) - globenewswire.com
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: -0.07%
H: 0.58%
C: -9.59%
covid vaccine phase 3 trial
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.